The efficacy and safety of donafenib combined with transcatheter arterial chemoembolization and anti-PD-1 antibodies as first-line therapy for hepatocellular carcinoma: A retrospective study

被引：0
|
作者：
Song, Danjun
Hao, Weiyuan
Cao, Fei
Luo, Jun
Guo, Liwen
Zhang, Zhewei
Zheng, Jiaping
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Dept Intervent Radiol, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16178
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
    Huang, Cheng
    Zhu, Xiao-Dong
    Shen, Ying-Hao
    Wu, Dong
    Ji, Yuan
    Ge, Ning-Ling
    Chen, Ling-Li
    Tan, Chang-Jun
    Zhou, Jian
    Fan, Jia
    Sun, Hui-Chuan
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [22] The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma
    Han, Fuxin
    Wu, Zhaozhen
    Chen, Jiaxin
    Liu, Meicen
    Hu, Yi
    CANCER MEDICINE, 2023, 12 (23): : 21129 - 21137
  • [23] Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
    Zhang, Weihong
    Zhu, Bowen
    Tang, Yiyang
    Xue, Miao
    Wu, Yanqin
    Zhao, Yue
    Fan, Wenzhe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Transcatheter arterial chemoembolization combined with sorafenib versus sorafenib for hepatocellular carcinoma: A retrospective study
    Liao, Min-Kai
    Lin, Che-Kuang
    Lin, Chih-Lin
    Lin, Tsung-Jung
    Chen, Kuan-Yang
    Liao, Li-Ying
    Wang, Chung-Kwe
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 333 - 333
  • [25] Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study
    Sun, Bo
    Zhang, Lijie
    Sun, Tao
    Ren, Yanqiao
    Cao, Yanyan
    Zhang, Weihua
    Zhu, Licheng
    Guo, Yusheng
    Gui, Yuxi
    Liu, Fengyong
    Chen, Lei
    Xiong, Fu
    Zheng, Chuansheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma
    Liu, Qing-Qing
    Wang, Xiang-Xu
    Ji, Hongchen
    Dou, Qiong-Yi
    Zhang, Hong-Mei
    MEDICAL ONCOLOGY, 2024, 41 (05)
  • [27] Organ specific tumour response to first-line (1L) therapy with combined lenvatinib (LEN) and anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma (HCC)
    Sun, H-C.
    Huang, C.
    Zhu, X-D.
    Shen, Y-H.
    Wu, D.
    Ge, N-L.
    Chen, Y.
    Tan, C-J.
    Zhou, J.
    Fan, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1308 - S1308
  • [28] Transarterial chemoembolization combined with donafenib or lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: A single-center real-world retrospective study.
    Liu, Huan
    Huang, Mingsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy
    Oh, Myung Jin
    Lee, Heon Ju
    Lee, Si Hyung
    CLINICAL AND MOLECULAR HEPATOLOGY, 2013, 19 (03) : 288 - 299
  • [30] A retrospective study on the efficacy and safety of donafenib combined with transarterial chemoembolization (TACE) and with/without immunotherapy in intermediate-advanced hepatocellular carcinoma (HCC).
    Chen, Cong
    Fu, Shouzhong
    Zhao, Suming
    Yuan, Hongxin
    Dai, Feng
    Gu, Weiwei
    Gu, Zhuxin
    Shi, Rongfeng
    Yang, Xiaohu
    Lu, Xiaohua
    Jia, Pengfei
    Si, Luyi
    Zhao, Hui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345